Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2008, Vol. 2 Issue (2) : 186-190     DOI: 10.1007/s11684-008-0035-9
|
Inhibitory activity of Bifidobacterium adolescent combined with cisplatin on melanoma in mice and its mechanism
HUANG Hongying, LIU Guangchao, QI Yijun, DU Yaowu, CHEN Jugao, MA Yuanfang
Key Laboratory of Cellular and Molecular Immunology, Institute for Immunology, Henan University;
Download: PDF(149 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  The aim of this study is to explore inhibitory activity of Bifidobacterium adolescent combined with cisplatin on the growth of melanoma (B16) in mice and the underlying mechanism. C57 mice were inoculated with B16 cancer cells to construct mouse model of melanoma and treated with bifidobacterium adolescent combined with cisplatin. Ratios of inhibitory activity on the growth of melanoma (B16) were calculated. Pathology changes of the tumor were observed by HE staining. B16 cell cycles were examined on a flow cytometer. Lymphocyte proliferation was measured with MTT assay and the T-cell subset was measured by double marked fluorescence. When bifidobacterium of 1010 cfu/L was injected, the ratio of inhibitory activity on the growth of melanoma (B16) reached 54%, which was similar to that of cisplatin group. The ratio of inhibitory activity reached 74.45% when the mice were treated by bifidobacterium combined with cisplatin. HE staining shows that bifidobacterium inhibited B16 cell proliferation and enhanced the cisplatins killing activity on B16 cells. The results of flow cytometry demonstrated that B16 cell proliferation was arrested at G1 stage after treatment with bifidobacterium. The B16 cell proliferation was arrested at S stage after treatment with cisplatin. The CD4+ percentage increased and the difference was significant compared with the normal group after treatment with bifidobacterium, indicating that T-cell immune activity was enhanced. Treatment with bifidobacterium combined with cisplatin can enhance the inhibitory activity on the growth of melanoma (B16) of cisplatin. The mechanism of the inhibitory activity on B16 cell proliferation is correlated with the enhanced immune activity in mice.
Issue Date: 05 June 2008
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-008-0035-9     OR     http://academic.hep.com.cn/fmd/EN/Y2008/V2/I2/186
1 Wang Y Mai T Liu M F Chen S H Effect of lipoteichoicacid of Bifidobacterium on survivin and its regulatory genesZhonghua Zhong Liu Za Zhi 2007 29(5)325328(in Chinese)
2 Pavne A G Exploitinghypoxia in solid tumors to achieve oncolysisMed Hypotheses 2007 68(4)828831.
doi:10.1016/j.mehy.2006.09.013
3 Fujimori M Geneticallyengineered bifidobacterium as a drug delivery system for systemictherapy of metastatic breast cancer patientsBreast Cancer 2006 13(1)2731.
doi:10.2325/jbcs.13.27
4 Le Leu R K Brown I L Hu Y Bird A R Jackson M Esterman A Young G P Asynbiotic combination of resistantstarch and Bifidobacterium lactis facilitates apoptotic deletion ofcarcinogen-damaged cells in rat colonJNutr 2005 135(5)9961001
5 Zeuthen L H Christensen H R Frokiaer H Lactic acid bacteria inducing a weak interleukin-12 andtumor necrosis factor alpha response in human dendritic cells inhibitstrongly stimulating lactic acid bacteria but act synergisticallywith gram-negative bacteriaClin VaccineImmunol 2006 13(3)365375.
doi:10.1128/CVI.13.3.365‐375.2006
6 Picard C Fioramonti J Francois A Robinson T Neant F Matuchansky C Reviewarticle: bifidobacteria as probiotic agents- physiological effectsand clinical benefitsAliment PharmacolTher 2005 22(6)495512.
doi:10.1111/j.1365‐2036.2005.02615.x
7 Wei A Zhao M Q li Y L li S Kang L Song W G Stimulatoryeffect of bifidobacteria DNA containing unmethylated CpG motifs onmaturation of bone marrow-derived dendritic cellsDi Si Jun Yi Da Xue Xue Bao 2006 27(2)113116(in Chinese)
8 Slingluff C L J r Chianese-Bullock KA Bullock T N Grosh W W Mulins D W Nichols L Olson W Petroni G Smolkin M Enqelhard V H Immunity to melanoma antigens:from self-tolerance to immunotherapyAdvImmunol 2006 90243295
9 Lambe T Leung J C Bouriez-Jones T Silver K Makinen K Crockford T L Ferry H Forrester J V Cornall R J CD4 T cell-dependentautoimmunity against a melanocyte neoantigen induces spontaneous vitiligoand depends upon Fas-Fas ligand interactionsJ Immunol 2006 177(5)30553062
10 Panelli M C Martin B Nagosen D Wanq E Smith K Monsurro V Marincola F M A genomic- and proteomic-basedhypothesis on the eclectic effects of systemic interleukin-2 administrationin the context of melanoma-specific immunizationCells Tissues Organs 2004 177(3)124131.
doi:10.1159/000079986
11 Martino D J Currie H Taylor A Conway P Prescott S L Relationship between early intestinal colonization,mucosal immunoglobulin A production and systemic immune developmentClin Exp Allergy 2008 38(1)6978
12 Xiong F Cheng Q Liu M F Chen S H Effect of Bifidobacteriumon the maturation and function of dendritic cell originating fromblood monocyteSichuan Da Xue Xue Bao YiXue Ban 2007 38(5)783787(in Chinese)
13 Ménard O Butel M J Gaboriau-Routhiau V Waligora-Dupriet A J Immuneresponse induced by Bifidobacterium strains isolated from infantsin gnotobiotic miceAppl Environ Microbiol 2007, Dec 14 [Epub ahead of print]
14 Iwabuchi N Takahashi N Xiao JZ Miyaji K Iwatsuki K In vitro Th1 cytokine-independent Th2 suppressiveeffects of bifidobacteriaMicrobiol Immunol 2007 51(7)649660
15 Medina M Izquierdo E Ennahar S Sanz Y Differentialimmunomodulatory properties of Bifidobacterium logum strains: relevanceto probiotic selection and clinical applicationsClin Exp Immunol 2007 150(3)531538
16 Kim D W Cho S B Lee H J Chunq W T Kim K H Hwanqbo J Nam I S Cho Y I Yang M P Chunq I B Comparison of cytokine and nitric oxideinduction in murine macrophages between whole cell and enzymaticallydigested Bifidobacterium sp. obtained from monogastric animalsJ Microbiol 2007 45(4)305310
17 Gueimonde M Ouwehand A Huhtinen H Salminen E Salminen S Qualitative and quantitative analyses ofthe bifidobacterial microbiota in the colonic mucosa of patients withcolorectal cancer, diverticulitis and inflammatory bowel diseaseWorld J Gastroentrrol 2007 13(29)39853989
18 Pavne A G Exploitinghypoxia in solid tumors to achieve oncolysisMed Hypotheses 2007 68(4)828831.
doi:10.1016/j.mehy.2006.09.013
19 Sasaki T Fujimori M Hamaji Y Hama Y Ito K Amano J Taniquchi S Genetically engineered Bifidobacteriumlongum for tumor-targeting enzyme-prodrug therapy of autochthonousmammary tumors in ratsCancer Sci 2006 97(7)649657.
doi:10.1111/j.1349‐7006.2006.00221.x
20 Coakley M Johnson M C McGrath E Rahman S Ross R P Fitzqerald G F Devery R Stanton C Intestinal bifidobacteria that produce trans-9, trans-11conjugated linoleic acid: a fatty acid with antiproliferative activityagainst human colon sw480 and ht-29 cancer cellsNutr Cancer 2006 56(1)95102.
doi:10.1207/s15327914nc5601_13
21 Ewaschuk J B Walker J W Diaz H Madsen K L Bioproductionof conjugated linoleic acid by probiotic bacteria occurs in vitroand in vivo in miceJ Nutr 2006 136(6)14831487
No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed